Dimethylargininase (DDAH)
Dimethylarginine Dimethylaminohydrolase
Dimethylarginase (DDAH) hydrolyzes asymmetric dimethylarginine (ADMA) to regulate the production of nitric oxide (NO) , and its two isozymes, DDAH1 and DDAH2, are expressed in various tissues. DDAH is a potential inhibitory target for diseases such as cardiovascular disease, neurodegenerative diseases, and cancer.
References:
- [1]. Dimethylargininase. Neuroscience. Sciencedirect.
- [2]. Gray GA, et al. Immunolocalisation and activity of DDAH I and II in the heart and modification post-myocardial infarction. Acta Histochem. 2010 Sep;112(5):413-23. [Content Brief]
- [3]. Murphy RB, et al. Inhibitors of the Hydrolytic Enzyme Dimethylarginine Dimethylaminohydrolase (DDAH): Discovery, Synthesis and Development. Molecules. 2016 May 11;21(5):615. [Content Brief]
All Product Categories
-
Dimethylargininase (DDAH) Related Products (3)
Related Products (3)
-
hDDAH-1-IN-1
0 ImagesCat. No.: HY-133126CAS No.: 1229238-69-0hDDAH-1-IN-1 (compound 8a) is a potent and selective non-amino acid catalytic site inhibitor of human dimethylarginine dimethylaminohydrolase-1 (hDDAH-1), with a Ki of 18 μM. DDAH mediates ADMA metabolism, thereby regulating nitric oxide production in a variety of disease states.
-
PD 404182 (Standard)
0 ImagesCat. No.: HY-16958RCAS No.: 72596-74-8Paris saponin VII (Standard) is the analytical standard of Paris saponin VII. This product is intended for research and analytical applications. Paris saponin VII (Chonglou Saponin VII) is a steroidal saponin isolated from the roots and rhizomes of Trillium tschonoskii. Paris saponin VII-induced apoptosis in K562/ADR cells is associated with Akt/MAPK and the inhibition of P-gp. Paris saponin VII attenuates mitochondrial membrane potential, increases the expression of apoptosis-related proteins, such as Bax and cytochrome c, and decreases the protein expression levels of Bcl-2, caspase-9, caspase-3, PARP-1, and p-Akt. Paris saponin VII induces a robust autophagy in K562/ADR cells and provides a biochemical basis in the treatment of leukemia.
